Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis

NCT03569293 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03569293
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03569293 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Lead sponsor
AbbVie
Phase
Phase 3
Overall status
Completed
Start date
August 13, 2018
Completion date
October 10, 2025
Enrollment
912 (actual)
Sites
180

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis